In contrast, the UGT2B28 KD cells across the three models exhibited a significant delay (an additional 2–11 days) in tumor take rates, with the palpable tumors appearing on Days 10, 14, and 32 post-injection in the LNCaP, LAPC-4 and VCaP xenograft models, respectively. This evidence concerns the gene UGT2B28 and neoplasm.